"93% (to plasma proteins)"@en . . . "Humans and other mammals"@en . . . . "Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting"@en . . . . . "(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide"@en . "A 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]"@en . . . . . . "Two theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release."@en . . "approved"@en . . "The major excretory route of dihydroergotamine is via the bile in the feces. Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection."@en . . "For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes."@en . . . . . "Dihidroergotamina"@en . . . "6190-39-2"@en . . . . "9,10-dihydroergotamine"@en . . . "* 800 L"@en . . " "@en . . "Dihydroergotaminum"@en . . "9 hours"@en . . "Interpatient variable and may be dependent on the administration technique"@en . "Dihydroergotamine"@en . . "Diidroergotamina"@en . . . . . . "Dihydroergotamin"@en . . . . "9,10-dihydro-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione"@en . . "5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman"@en . . . . . . . . . . . . . "* 1.5 L/min"@en . . . . . "Dihydroergotamine"@en . " "@en . . . . . . . . . . .